ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Lilly to acquire axon-loss-prevention start-up Disarm Therapeutics

by Ryan Cross
October 24, 2020 | APPEARED IN VOLUME 98, ISSUE 41

 

Eli Lilly and Company will acquire the Cambridge, Massachusetts–based start-up Disarm Therapeutics for $135 million. Disarm is developing small-molecule inhibitors of SARM1. Two of the company’s cofounders, Jeffrey Milbrandt and Aaron DiAntonio of Washington University School of Medicine in St. Louis, discovered that the protein promotes the degeneration of the nervous system’s axons after injury. Blocking SARM1 could deter axon loss in neurological diseases such as amyotrophic lateral sclerosis and multiple sclerosis, Lilly says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment